04:06 AM EDT, 10/27/2026 (MT Newswires) -- AstraZeneca (AZN.L, AZN.ST) and Japanese drugmaker Daiichi Sankyo's Enhertu received European Union approval as an adjuvant treatment for adults with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant treatment. The approval was supported by the positive opinion of the European Medicines Agency's Committee for Medicinal Products for Human Use and the positive results from the DESTINY-Breast05 phase 3 trial, according to a Tuesday release. The approval, Enhertu's first in the EU for early breast cancer in the curative-intent setting, triggers a $75 million milestone payment from AstraZeneca to Daiichi Sankyo.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.